Stakeholder perspectives on decision-Analytic modeling frameworks to assess genetic services policy

Genetics in Medicine

Volumn 15, Issue 1, 2013, Pages 84-87

  Guzauskas, Gregory F ^a   Garrison, Louis P ^a   Stock, Jacquie ^b   Au, Sylvia ^c   Doyle, Debra Lochner ^d   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Seattle Children's Center for Children with Special Needs   (United States)

^c HAWAII STATE DEPARTMENT OF HEALTH   (United States)

^d WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

comparative effectiveness research; decision support techniques; economic; genetic testing; health; high throughput nucleotide sequencing; insurance; models; reimbursement

Indexed keywords

ANONYMOUS TESTING; CHROMOSOME ANALYSIS; CLINICAL DECISION MAKING; CONCEPTUAL FRAMEWORK; CONTENT ANALYSIS; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; GENE SEQUENCE; GENETIC SCREENING; GENETIC SERVICE; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; MEDICAID; MICROARRAY ANALYSIS; MULTIPLE DISORDER TESTING; NEXT GENERATION SEQUENCING; PATIENT SATISFACTION; REIMBURSEMENT; REVIEW;

DECISION MAKING; DECISION SUPPORT TECHNIQUES; GENETIC SERVICES; GENETIC TESTING; HEALTH SURVEYS; HUMANS; INSURANCE COVERAGE; QUESTIONNAIRES;

EID: 84872053441     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.92     Document Type: Review

References (13)

1. Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. A formal riskbenefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice. Genet Med. 2010;12:686-693.
2. Ramsey SD, Veenstra DL, Garrison LP Jr, et al. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. Am J Manag Care 2006;12:197-202.
3. Khoury MJ, Coates RJ, Evans JP. Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genet Med 2010;12:680-683.
4. Roth JA, Garrison LP Jr, Burke W, Ramsey SD, Carlson R, Veenstra DL. Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics 2011;14:59-67.
5. Garrison LP Jr, Austin MJ. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Aff (Millwood) 2006;25:1281-1290.
6. Garrison LP Jr, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metab Rev 2008;40:377-401.
7. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in Health and Medicine. Oxford University Press: Oxford, UK, 1996.
8. Drummond MF, Sculpher MJ, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press: Oxford, UK, 2005.
9. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001;4:348-361.
10. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003;6:9-17.
11. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010;28:61-74.
12. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res 2005;15:1277-1288.
13. Berg JS, Khoury MJ, Evans JP. Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med 2011;13:499-504.